| Literature DB >> 30057345 |
Eddy H C Wang1, Brigitte N Sallee1, Christina I Tejeda2, Angela M Christiano3.
Abstract
The advancement of genetic and preclinical studies has uncovered the mechanisms involved in the pathogenesis of alopecia areata (AA). The development of targeted therapies using small molecules blocking specific pathways for the treatment of AA is underway. By repurposing Food and Drug Administration-approved small molecule JAK inhibitors as treatments for AA, it has been demonstrated that JAK inhibitors can effectively reverse hair loss in patients with moderate to severe AA. In this review, we summarize and discuss the current preclinical and clinical studies on JAK inhibitors, as well as the prospects of using JAK inhibitors for the treatment of AA.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30057345 PMCID: PMC6475885 DOI: 10.1016/j.jid.2018.05.027
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551